Janssen Biotech, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, will acquire BeneVir Biopharm, a privately-held, biopharmaceutical company specializing in the development of oncolytic immunotherapies.
BeneVir utilizes a proprietary T-Stealth™ Oncolytic Virus Platform to engineer oncolytic viruses, tailored to infect and destroy cancer cells. Janssen intends to advance pre-clinical candidates as standalone therapies and in combination with other immunotherapies for the treatment of solid tumor cancers (e.g., lung, prostate, colorectal, etc.).
BeneVir will maintain a research presence in Rockville, Maryland, USA, and become part of the Janssen Oncology Therapeutic Area. The team will remain focused on the optimization of next generation T-Stealth™ oncolytic viruses in solid tumors and the execution of pre-clinical activities.